Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy + Chemoradiotherapy for ESCC
NCT06478355Active, not recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jan 2018
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoints: Objective Remission Rate up to 100 months and Incidence of Treatment-Emergent Adverse Events up to 100 months. Started Jan 2018; status: active, not recruiting.
02
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06478355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478355.